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Abstract 
The BRAF inhibitor vemurafenib is an effective drug in patients with BRAF mutant 
metastatic melanoma, but resistance occurs after a median of 6 months. The anti-
CTLA4-antibody, ipilimumab, is a standard first-line and second-line treatment option 
in Europe, with a median time to response of 2–3 months, but some patients show 
rapid clinical deterioration before that. The aim of this analysis was to identify 
prognostic markers for survival after failure of vemurafenib treatment to identify 
patients who have a sufficient life expectancy to respond to new immunotherapy 
treatments. We retrospectively analysed 101 consecutive unselected patients treated 
with vemurafenib for metastatic melanoma at a single institution. The association 
between clinical parameters and death within 3 months after cessation of 
vemurafenib (n=69) was assessed by binary logistic and Cox regression. Of the 
patients, 45% died within 3 months of progression on vemurafenib. Elevated 
baseline serum lactate dehydrogenase, absence of normalization of serum lactate 
dehydrogenase on vemurafenib therapy, performance status of at least 2 at 
progression and time from primary tumour to metastatic disease less than 5 years 
were identified as poor prognostic markers. In an exploratory tumour growth kinetics 
analysis (n=16), we found that following cessation of vemurafenib, approximately a 
third each showed a stable, decelerated or accelerated rate of tumour growth. 
Patients with these poor prognostic markers are unlikely to have sufficient life 
expectancy to complete ipilimumab treatment after failure with vemurafenib. 
Consideration needs to be given to the elective use of immunotherapy before 
patients become resistant to vemurafenib. This requires prospective randomized 
evaluation. Our tumour growth kinetics analysis requires confirmation; however, it 
may suggest that intermittent vemurafenib treatment should be investigated in 
clinical trials. 
  
Introduction 
Malignant melanoma is currently the ninth most common cancer in Europe, and 
incidence rates have been increasing worldwide (http://www.cancer.org; 
http://www.cancerresearchuk.org). Until recently, therapeutic options for patients with 
metastatic melanoma were limited, and 5-year survival rates of 10–20% largely 
reflected the natural history of the disease. 
Major treatment advances have been made over the past 4 years, with the approval 
of five agents by the European Medical Association for the treatment of metastatic 
melanoma: in 2011, ipilimumab [1] – an anti-CTLA4 antibody – and vemurafenib [2] 
– a selective BRAF inhibitor – were approved. More recently, the BRAF inhibitor, 
dabrafenib, and the MEK inhibitor, trametinib, were also approved [3,4]. In addition, 
the new anti-PDL1-agent, pembrolizumab, and the anti-PD1-agent, nivolumab, have 
been approved. 
Approximately 40% of melanomas harbour activating mutations in the protein kinase 
BRAF (Catalogue of Somatic Mutations in Cancer database). In metastatic 
melanoma patients harbouring a BRAF V600 mutation, treatment with vemurafenib 
results in improved progression-free survival (PFS) and overall survival (OS) 
compared with chemotherapy with dacarbazine, especially in patients with large 
tumour burden [5–7]. The most important limitation of BRAF-targeted therapy is the 
relatively short duration of the antitumour effect: the median PFS is 6–7 months and 
resistance is almost universal. 
In contrast, immunotherapy has limited response rates of 10–20% with ipilimumab 
and 30% with pembrolizumab or nivolumab in metastatic melanoma; however, 
longterm control can be achieved in some patients independent of the BRAF 
mutation status, and better responses are often seen in patients with lower tumour 
burden [1, 8–10]. Until late 2013, ipilimumab was licensed only in Europe as a 
second or subsequent line of treatment.Therefore, until recently, in Europe, outside 
of the context of clinical trials, standard treatment for BRAF mutant melanoma 
consisted of vemurafenib followed by ipilimumab. Immunotherapy typically requires 
at least 8–12 weeks for a response to be seen, and consequently, patients 
embarking on this therapy need to have a life expectancy of at least 3 months. 
Clinical experience suggests that patients with rapidly growing disease after 
progression on vemurafenib do not benefit from immunotherapy [9]. To date, apart 
from adequate performance status (PS), prognostic markers of potential benefit have 
not been defined. However, we have shown that a serum lactate dehydrogenase 
(LDH) level greater than two times the upper limit of normal is a negative prognostic 
marker for long-term benefit from ipilimumab [11]. 
We carried out a retrospective analysis to identify prognostic parameters and which 
patients have a sufficient life expectancy to respond to new immunotherapy 
treatments following progression on vemurafenib. We also carried out an exploratory 
comparative analysis of tumour growth kinetics during progression on vemurafenib 
and after the cessation of the drug but before the instigation of subsequent therapy. 
 
Methods 
Patients 
In this retrospective case series, we analysed all patients who had been treated with 
and progressed on vemurafenib as a single-agent therapy for metastatic melanoma 
harbouring a BRAF V600 mutation at a single institution (Royal Marsden Hospital, 
London, UK) from March 2010 to May 2013. Patients were treated with vemurafenib 
within the BRAF inhibitor in Melanoma (BRIM-3) study (NCT01006980, enrolment 
period March 2010 until December 2010), the vemurafenib safety study 
(NCT01307397, enrolment period March 2011 until January 2013) as well as off trial 
after approval from the European Medicines Agency in December 2011. Exclusion 
criteria were treatment with vemurafenib for malignancies other than melanoma, 
cessation of vemurafenib for reasons other than progressive disease, such as 
toxicity, and lack of radiological confirmation of progressive disease, for example, 
death before radiological confirmation of progressive disease. 
The primary aim of the analysis was the identification of the proportion of patients 
with early death (ED; defined as death ≤90 days after progression on vemurafenib) 
and their clinical characteristics compared with patients with late death (LD; defined 
as death >90 days after progression on vemurafenib). Any patient who was alive but 
had not yet reached at least 90 days of follow-up after cessation of treatment were 
not included in the ED/LD analysis. We also described the PFS, OS and prognostic 
markers for OS for all patients analysed. 
In an exploratory analysis, we measured tumour growth rates (TGRs) while patients 
were progressing on vemurafenib compared with those after stopping vemurafenib 
but before subsequent therapy or best supportive care was instigated. Only patients 
who had not/not yet started further treatment after stopping vemurafenib were 
included in the analysis. TGRs were measured as percentage per week and 
assessed using a modified form of Response Evaluation Criteria In Solid Tumours 
(RECIST 1.1) by two independent observers: TGRs were calculated as the change 
in the sum diameters of the target lesions and up to five new lesions between the 
most recent computed tomography (CT) scan before and at the time of stopping 
vemurafenib (TGR1) and between the CT scan at cessation of vemurafenib and the 
subsequent CT scan after stopping vemurafenib (TGR2). An increase of at least 5% 
per week between TGR1 and TGR2 (ΔTGR) was considered as accelerated, −5% 
>ΔTGR< 5% per week was considered stable and ΔTGR of up to −5% per week was 
considered as decelerated tumour growth. These cutoff values correspond to 20% 
tumour growth as per RECIST 1.1 – that is, progressive disease over a 4-week 
interval. 
Statistical methods 
All statistical analyses were carried out using the SPSS software, version 21.0 
(SPSS Inc., Chicago, Illinois, USA). Univariate binary logistic regression analyses 
were used to test for any variable associated with ED. Univariate Cox regression 
analyses were used to test for any variable associated with OS. P-values less than 
0.05 were considered significant. Variables with P less than 0.05 were entered into a 
multivariate model in a forward stepwise manner. PFS, postprogression survival 
(PPS) and OS analyses were carried out using the Kaplan–Meier method. PFS was 
defined as the time from the start of vemurafenib to progression. PPS was defined 
as the time from cessation of vemurafenib until death. OS was defined as the time 
from the start of vemurafenib until death. Patients alive at time of evaluation were 
censored at the last follow-up (cutoff 30 September 2013). Patients lost to follow-up 
were censored at the last follow-up. 
 
Results 
Clinical characteristics of patients with progression on vemurafenib 
Between March 2010 and May 2013, 101 patients were treated with vemurafenib as 
a single agent for metastatic melanoma. At the time of evaluation, 69 (68%) had 
stopped vemurafenib for radiologically confirmed progressive disease (Table 1). This 
formed the case series population. 
The patients were treated outside trials, within the vemurafenib safety study and 
within the BRIM-3 study (20, 70 and 10%, respectively). An overview of the clinical 
characteristics of all patients who progressed on vemurafenib is given in Table 2. 
The majority of the patients were treatment-naive before starting vemurafenib (70%): 
21 (30%) patients had undergone at least one systemic treatment before 
vemurafenib, including two patients having being treated with ipilimumab. Before 
commencing vemurafenib, 70% of the patients had an elevated LDH, 16% had an 
Eastern Cooperative Oncology Group PS of at least 2 and 20% had central nervous 
system (CNS) disease; 26% of the patients had two of these three characteristics, 
and one patient had all three. 
The median follow-up from starting vemurafenib was 20.4 months [95% confidence 
interval (CI): 15.4–25.4]. The median PFS was 4.1 months (95% CI: 2.7–5.6; Table 
3). The median PPS was 3.2 months (95% CI 2.2–4.2). In nine of 69 patients the 
date of death was unknown because of loss to follow-up. 
Post vemurafenib therapy 
After progression on vemurafenib, 28 patients (41%) received further active therapy 
(Table 2); the same proportion of patients received best supportive care because of 
clinical deterioration, according to the his/her preference and/or as ipilimumab was 
not yet available at the time of progression. Thirteen patients (19%) were lost to 
follow-up. Out of the 56 patients in whom postvemurafenib management is known, 
21 (38%) received subsequent treatment with ipilimumab and seven (12%) received 
other systemic therapies, but only eight of these patients were able to complete the 
full course of four doses of ipilimumab. This represents 14% of the total population in 
whom follow-up management is known and 38% of those who commenced 
ipilimumab. Seven died before completion of ipilimumab therapy, and three patients 
discontinued ipilimumab for progression on treatment (Table 2). All patients who 
were treated with ipilimumab had a PS of up to 1 before starting this therapy. All 
patients who completed four doses of ipilimumab had a normal baseline LDH before 
starting vemurafenib or an elevated baseline LDH that normalized while on treatment 
with vemurafenib. One of those eight patients (12%) responded to ipilimumab, 
whereas the others showed progressive disease. 
Prognostic impact of clinical features 
We explored the prognostic significance of clinical parameters in all patients who 
progressed on vemurafenib: age, sex, CNS involvement at baseline, progression 
within the CNS, elevated LDH at baseline and at progression, absence of 
normalization of LDH on vemurafenib, PS at baseline and progression, time between 
diagnosis of the primary tumour and development of metastatic disease and stage of 
metastatic disease at the start of vemurafenib. 
In multivariate analysis, PS of at least 2 at progression and time between diagnosis 
of the primary tumour and development of metastatic disease less than 5 years were 
associated with poor OS [hazard ratio (HR) 3.4 (95% CI: 1.7–7.0), P =0.001 and HR 
6.4 (95% CI: 2.5–16.4), P <0.001, respectively; Table 4]. 
Patients with elevated baseline LDH levels showed a tendency towards poorer OS 
compared with those with normal LDH [HR 1.8 (95% CI: 1.0–3.3), P = 0.06]. 
However, the absence of normalization of LDH was an independent marker for poor 
OS [HR 8.6 (95% CI: 2.8–26.6), P <0.001; Table 4]. No difference in outcome was 
seen between patients with normal baseline LDH levels and those with elevated 
baseline LDH levels that normalized (Fig. 1). Approximately two-thirds of the patients 
(60%) with LDH normalization showed a second rise in LDH before subsequent 
progressive disease. In 87% of patients, progression occurred within the next 2 
months, with a median time to progression of 29 days (range 0–168) from secondary 
abnormal LDH. 
Prognostic markers for early death 
Thirty-one of 69 patients (45%) died within 90 days (ED), whereas 30 patients (43%) 
survived longer than 90 days (LD; Table 2). Eight patients had not yet reached 90 
days since stopping vemurafenib at the time of the analysis and were excluded from 
the analysis.There were no differences between patients with ED/LD in relation to 
age, sex, stage of metastatic disease, prior treatment or PS at baseline. Elevated 
prevemurafenib baseline LDH [odds ratio (OR) 5.5 (95% CI: 1.3–23.0), P = 0.02], PS 
of at least 2 at the time of progression [OR 6.9 (95% CI: 1.6–29.4), P= 0.01] and time 
between diagnosis of the primary tumour and development of metastatic disease 
less than 5 years [OR 12.8 (95% CI: 1.9–83.3), P = 0.008] were correlated with ED 
(Table 4). All patients who had elevated baseline LDH before vemurafenib treatment 
and never showed normalization of their LDH (n =8) belonged to the ED group. 
Influence of stopping of vemurafenib on tumour growth 
We analysed the preprogression and postprogression tumour growth kinetics in 16 
out of the 69 patients (three ED patients, 12 LD patients and one patient who had not 
yet reached 90 days of follow-up) in whom postprogression CT scanning was 
performed following the cessation of vemurafenib treatment and before the 
instigation of further active therapy or best supportive care. The reasons for the lack 
of evaluable CT were as follows: immediate initiation of a further treatment (n =15), 
palliative care without a further scan (n =27), external CT (n= 7), partial CT (n= 3) 
and no subsequent scan yet at the time of evaluation (n =1). 
The median time between CT scans before and at the time of stopping vemurafenib 
was 8 weeks (range 4–12 weeks). The median time between CT scans at and after 
stopping vemurafenib was 5 weeks (range 4–14 weeks). The median TGRs before 
and after progression on vemurafenib were +6.1% per week (range − 3.5 to 
+156.5%) and + 14.7% per week (range +0.7 to +45.2%), respectively – that is, a 
2.4-fold median increase in growth rate. Seven out of 16 patients (44%) showed an 
acceleration of tumour growth, with ΔTGR of at least 5% per week after stopping 
vemurafenib (Fig. 2a), whereas in five patients (31%), the tumour growth was stable 
(− 5%>ΔTGR<5% per week; Fig. 2b), and in four patients (25%), a deceleration in 
tumour growth was seen (ΔTGR≤−5% per week; Fig. 2c). The median OS for these 
three groups was 9.0 (range 2.0–13.0), 10.0 (range 3.0–20.0) and 11.0 (range 8.0–
23.0) months, respectively. None of the patients with decelerated TGR had received 
immunotherapy before vemurafenib. Three out of 16 patients (two with decelerated 
TGR and one with accelerated TGR) received ipilimumab after vemurafenib. One 
each completed the full course of ipilimumab, but both showed subsequent 
progression. 
 Discussion 
Our data demonstrate that a significant number of patients with progressive disease 
on vemurafenib do not have sufficient life expectancy to potentially complete 
subsequent treatment with ipilimumab or to even respond to new immunotherapy, 
and others have made a similar observation [12]. In this analysis, the median 
survival was 3.2 months, with 45% of patients dying within 3 months (ED) of stopping 
vemurafenib. An elevated baseline LDH, PS of at least 2 at progression and time 
between diagnosis of the primary tumour and development of metastatic disease 
less than 5 years were correlated with ED. All three parameters are well-known 
prognostic factors for metastatic melanoma. 
Despite our limited sample size, these data suggest that if ipilimumab is to be 
administered after vemurafenib, then serious consideration needs to be given to a 
vemurafenib ‘induction’ strategy. For example, patients could receive vemurafenib 
until maximum response, normalization of poor prognostic factors or for an arbitrary 
period such as 8–16 weeks (two to four cycles), followed by immunotherapy utilizing 
immune checkpoint inhibition. In a recent small series, all 11 patients treated early 
with ipilimumab after two to four induction cycles of vemurafenib were alive at a 
median follow-up of 1 year, compared with seven out of eight patients who were 
reported to have died on switching to vemurafenib on progression [13]. This strategy 
of elective sequential hybrid therapy of targeted agent immunotherapy requires 
prospective evaluation. A current prospective trial investigates how BRAF/MEK 
inhibitor treatment and immunotherapy treatment should be sequenced in patients 
with advanced BRAF mutant melanoma (NCT02224781). 
We have found that our patients with an elevated baseline LDH that normalized 
while on vemurafenib showed a significantly better OS than patients without 
normalization of this serum enzyme. The normalization of LDH may also be 
important when we try to predict who will benefit from postvemurafenib ipilimumab. 
Only eight patients (14%) out of the 56 patients in whom postvemurafenib treatment 
is known were able to receive all four doses of ipilimumab; normalization of LDH 
while on vemurafenib was a feature of those who were able to complete this 
immunotherapy. A previously reported case series of 28 patients treated with BRAF 
inhibitors followed by ipilimumab suggested clinical baseline markers such as 
elevated baseline LDH, PS greater than 0 and CNS involvement to be indicators of 
failure of completion of second-line treatment [14]. The relationship between 
normalization of LDH and the ability of patients to receive or complete subsequent 
therapy is important as it impacts how we sequence new treatments and design 
elective sequential hybrid therapy. 
Our exploratory study of TGR suggests that a majority of patients will show a steady 
or even an accelerated pace of disease after cessation of vemurafenib, but 
approximately one-third showed a deceleration of tumour growth. Although the 
accuracy of the method that we used is limited and the number of patients with 
accelerated tumour growth is likely to be underestimated in this selective analysis as 
a significant number had no subsequent CT scanning after stopping of vemurafenib, 
our findings imply that tumour evolutionary pressure is not always towards a more 
malignant phenotype. Preclinical data have demonstrated increased tumour 
proliferation of resistant tumours only in the presence of vemurafenib; however, 
following drug cessation, tumour regression was observed [15]. This finding is 
consistent with our tumour kinetic analysis, which shows that following cessation 
ofvemurafenib, 25% of patients had a deceleration of TGR. An obvious clinical 
consequence of this observation is that intermittent dosing of targeted agents may 
be a therapeutic strategy for some patients. Indeed, this approach has been shown 
to delay the onset of drug resistance in mice [15]. 
Rationally designed prospective clinical trials based on observations such as those 
presented here are urgently required to try and improve outcomes for patients by 
maximizing the relatively limited benefit from our existing therapies. 
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TABLES AND FIGURES 
 
Table 1: Overview of patients on vemurafenib 
 
 n (% of total) 
Total patients on vemurafenib  101 
Cessation of vemurafenib at the time of evaluation  87 (86) 
     Cessation of vemurafenib for progressive disease 69 (68) 
     Cessation of vemurafenib for toxicities 6 (6) 
     Progressive disease not confirmed radiologically before cessation of          
vemurafenib 
12 (12) 
No cessation of vemurafenib at time of evaluation 14 (14) 
 
  
Table 2: Clinical characteristics of all patients with progression on vemurafenib, 
those with early death (death ≤3 months after progression on vemurafenib) and 
those with late death (death >3 months after progression on vemurafenib) 
 
 All Early death Late death 
Total (n) 69 31 30 
Baseline    
    Age (range) (years)  52.7 (18–
77) 
52.4 (18–
77) 
52.3 (22–
74) 
    Male [n (%)] 40 (58) 19 (61) 15 (50) 
    Female [n (%)] 29 (42) 12 (39) 15 (50) 
    Time from primary tumour to 
metastatic disease <5 years [n (%)]  
53 (77) 29 (94)* 20 (67) 
    Systemic treatment before    
vemurafenib [n (%)] 
21 (30) 9 (29) 10 (33) 
    Stage M1c [n (%)]  55 (80) 28 (90) 21 (70) 
    Normal LDH [n (%)] 21 (30) 4 (13) 14 (47) 
    Elevated LDH [n (%)] 48 (70) 27 (87)* 16 (53) 
    PS 0/1 [n (%)]  58 (84) 23 (74) 27 (90) 
    PS ≥2 [n (%)] 11 (16) 8 (26) 3 (10) 
    CNS involvement [n (%)]) 14 (20 8 (26) 5 (17) 
On treatment with vemurafenib    
    LDH, normalized [n (%)] 38/48 (79) 19/27 (70) 16/16 (100) 
    LDH, not normalized [n (%)]  10/48 (21) 8/27 (30) – 
    Elevated LDH at progression [n (%)] 34 (49) 19 (61) 12 (40) 
    PS ≥2 at progression [n (%)] 26 (38) 18 (58)* 5 (17) 
Postprogression treatment [n (%)] 28 (41) 7 (23)** 20 (67) 
  Ipilimumab 21 (30) 5 (16) 14 (47) 
    Completed ipilimumab 8/21 (38) – 8/14 (57) 
    Discontinued ipilimumab (PD/death) 10/21 (48) 5/5 (100) 5/14 (36) 
    Discontinued ipilimumab (toxicities) 2/21 (10) – 1/14 (7) 
    Lost to follow-up  1/21 (5) – – 
 
CNS, central nervous system; LDH, lactate dehydrogenase; n, number of patients; 
PD, progressive disease; PS, performance status.P-values indicate correlation 
between clinical variables and early death.(*P<0.05; **P<0.001.) 
  
Table 3: Clinical and radiological outcome of all patients with progression on 
vemurafenib and of patients with early death (death ≤3 months after progression on 
vemurafenib) and late death (death >3 months after progression on vemurafenib) 
 
 All Early death Late death 
Total (n)  69 31 30 
Clinical outcome    
    1-year OS rate (95% CI) (%) 27 (15–39) 3 (0–9) 47 (29–66) 
    Median OS (95% CI) (months ) 8.5 (6.7–10.2) 4.4 (3.7–5.2) 11.7 (10.2–13.1) 
    Median PFS (95% CI) (months) 4.1 (2.7–5.6) 3.7 (3.5–3.9) 6.4 (5.2–7.7) 
    Median PPS (95% CI) (months) 3.2 (2.2–4.2) 1.3 (0.6–2.0) 5.1 (3.9–6.3) 
Radiological outcome    
    Clinical benefit (CR, PR, SD) [n 
(%)]  
60 (87) 26 (84) 29 (97) 
    Primary refractory disease [n 
(%)]  
9 (13) 5 (16) 1 (3) 
    Best response after cycle 2 [n 
(%)]  
54 (78) 29 (93) 20 (60) 
    Median time from BL to BR 
(95% CI) (months)  
1.8 (1.2–7.1) 1.7 (1.2–7.1) 1.8 (1.2–5.5) 
    Median time from BR to PD 
(95% CI) (months)  
2.0 (0.1–12.9) 1.9 (0.1–12.9) 3.7 (0.2–11.7) 
 
BL, baseline; BR, best response; CI, confidence interval CR, complete remission; 
OS, overall survival; PD, progressive disease; PFS, progression-free survival; 
PPS,postprogression survival; PR, partial response; SD, stable disease. 
 
  
Table 4: Prognostic factors for early death and overall survival:multivariate analysis 
 OR 95% CI P-value 
Prognostic factors for early death    
    Time from primary tumour to 
metastatic disease <5 years 
12.82  
 
1.93–83.33 0.008 
    PS at progression ≥2  6.86 1.60–29.42 0.010 
    Elevated LDH at baseline  5.48 1.31–23.01 0.020 
 HR 95% CI P-value 
Prognostic factors for overall survival    
    Time from primary tumour to 
metastaticdisease <5 years 
6.41  
 
2.49–16.39 <0.001 
    Normal LDH at baseline (reference) 1 
 
  
         LDH, normalized  
 
1.17 0.56–2.41 0.680 
         LDH, not normalized  
 
8.62 2.80–26.61 <0.001 
         Overall  
 
  <0.001 
     PS at progression ≥2  3.45 1.70–7.02 0.001 
 
Elevated LDH at baseline, LDH, normalized and not normalized, PS ≥2 at 
progression, time from primary tumour to metastatic disease ≥5 years were all 
entered into a multivariate model in a forward conditional selection manner. CI, 
confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase; PS, performance 
status. 
  
Figure 1: Overall survival curves of patients with normal baseline LDH and elevated 
baseline LDH with normalization and without normalization. Overall survival was 
defined as time from start of vemurafenib until death. Vertical lines indicate that the 
patients’ data were censored. The median follow-up period on vemurafenib was 20.4 
months. No significant difference in overall survival was observed between patients 
with normal baseline LDH and those with normalized LDH. CI, confidence interval; 
HR, hazard ratio; LDH, serum lactate dehydrogenase. 
 
 
 
  
Figure 2: Tumour growth rates (TGR) before and after progression on vemurafenib. 
TGR1 [left side of the panels (a), (b) and (c)]: tumour growth rate before progression 
on vemurafenib; TGR2 [right side of panels (a), (b) and (c)]: tumour growth rate after 
progression on vemurafenib. Change in TGR (ΔTGR) was calculated as difference 
between TGR1 and TGR2. (a) Patients with accelerated TGR; (b) patients with 
stable TGR; (c) patients with decelerated TGR. Legends of panels (a), (b) and (c) 
include the sum of the target lesions in mm at the time of cessation of vemurafenib. 
** Patients with early death. 
 
